Mean intraocular pressure and progression based on corneal thickness in primary open-angle glaucoma

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
William C StewartJeanette A Stewart

Abstract

The aim of this study was to evaluate the association of corneal thickness on the incidence of glaucomatous progression at individual levels of intraocular pressure. A retrospective, noninterventional evaluation of patients with primary open-angle glaucoma who were either stable over 5 years or had glaucomatous progression before 5 years of follow-up was performed. Each patient had central thickness corneal measurements documented. We included 310 patients in this study. Patients with thicker (at least 0.571 mm, n = 77) and mid-range corneas (0.511-0.570 mm, n = 177) progressed in 14% (n = 11) and 18% (n = 31) of cases, respectively. The progression rate for patients with a mean pressure of less than 17 mmHg in both groups was 12%-13%. In contrast, the progression rate in patients with 18 mmHg or higher was 23% and 16% in the mid-range and thick corneal groups, respectively. In patients with thinner corneas (equal to or less than 0.510 mm, n = 56), the progression rate was 32% (n = 18). The progression rate was 60% (12 of 20) with mean pressures of at least 18 mmHg or higher, but 18% with mean pressures equal to or less than 17 mmHg. Univariant (P = 0.05), but not multivariant, analysis showed that corneal thickness was a risk ...Continue Reading

References

Apr 1, 1978·Archives of Ophthalmology·M JohnsonW J Grodzki
Sep 1, 1975·Acta Ophthalmologica·N EhlersH Aasved
Aug 16, 1984·The New England Journal of Medicine·L E MosesH Hosseini
Aug 15, 1993·American Journal of Ophthalmology·W C StewartG Sethuraman
May 15, 1993·American Journal of Ophthalmology·M M WhitacreK Hassanein
Dec 1, 1996·American Journal of Ophthalmology·W C StewartC LoPresto
Feb 4, 1999·Archives of Ophthalmology·R F Brubaker
Jul 6, 2000·Journal of Glaucoma·K F Damji, R Munger
Oct 6, 2000·American Journal of Ophthalmology·W C StewartJ B Cantrell
Sep 6, 2003·Advances in Therapy·Peter A NetlandUNKNOWN Travoprost Study Groups
Oct 30, 2003·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Thom J ZimmermanUNKNOWN Latanoprost Axis Study Group
Nov 5, 2003·American Journal of Ophthalmology·Felipe A MedeirosRobert N Weinreb
Jan 14, 2004·Archives of Ophthalmology·Leon W HerndonSandra S Stinnett
Jan 14, 2004·Archives of Ophthalmology·Anastasios G P KonstasWilliam C Stewart

❮ Previous
Next ❯

Citations

May 25, 2010·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Ruojin RenJost B Jonas
Feb 24, 2009·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Gong Je SeongWilliam C Stewart
Oct 19, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Anastasios G P KonstasWilliam C Stewart
Jan 2, 2008·Ophthalmology·William C StewartMarko A Mychaskiw
Jul 14, 2007·Ophthalmology·M Cristina LeskeUNKNOWN EMGT Group
Jan 2, 2007·Ophthalmology·Anastasios G P KonstasWilliam C Stewart
Jun 4, 2008·Optometry and Vision Science : Official Publication of the American Academy of Optometry·Balwantray C Chauhan
Nov 3, 2009·European Journal of Ophthalmology·Abiye M AlemuWilliam C Stewart

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.